DGAT1 and obesity due to melanocortin 4 receptor deficiency: The proven viability of DGAT1 null mice initially led to an increase in research into DGAT1 inhibitors for obesity related diseases, but there have since been DGAT1 inhibitors developed for a variety of medical uses, from type 2 diabetes to tumour suppression (Smith et al., 2000).